Comparison
NMN vs Idebenone
NMN
Nicotinamide mononucleotide — NAD+ precursor. Studied for cellular aging and metabolic health.
Idebenone
Synthetic analog of CoQ10. Crosses the BBB more efficiently than CoQ10 itself. Approved in Europe and Japan for some neurological conditions.
| Field | NMN | Idebenone |
|---|---|---|
| Category | neuroprotective | neuroprotective |
| Dose range | 250–1000mg | 90–270mg |
| Half-life | — | — |
| Onset | — | — |
| Evidence | EVIDENCEB | EVIDENCEB |
| Safety | ●●●●● | ●●●●○ |
| Legal (US) | USOTC | USOTC |
| PubMed refs | 600 | 1100 |
The comparison in plain English
Auto-generated from dataNMN and Idebenone are both in the neuroprotective category respectively. NMN Nicotinamide mononucleotide — NAD+ precursor. Idebenone Synthetic analog of CoQ10.
Bottom line
NMN (evidence B, safety 5/5) matches the evidence base of Idebenone (evidence B, safety 4/5). NMN has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.
Choose NMN if
NMN is the better fit when your goal aligns with its mechanism (Direct precursor to NAD+ — one biosynthetic step closer than nicotinamide riboside, bypassing the NRK1/NRK2 enzymatic step) and the dose range (250–1000mg) suits your protocol. Half-life is —h.
Choose Idebenone if
Idebenone is the better fit when your goal aligns with its mechanism (Structural analog of CoQ10 with shorter side chain, producing better water solubility and BBB crossing) and the dose range (90–270mg) suits your protocol. Half-life is —h.